Neal Flomenberg Sells 88,519 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 88,519 shares of Tevogen Bio stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90. Following the transaction, the insider now directly owns 4,040,485 shares of the company's stock, valued at approximately $4,444,533.50. This trade represents a 2.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Neal Flomenberg also recently made the following trade(s):

• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The stock was sold at an average price of $1.28, for a total value of $18,737.92.

Tevogen Bio Stock Down 7.0 %

NASDAQ:TVGN traded down $0.08 on Monday, reaching $1.06. 620,487 shares of the stock traded hands, compared to its average volume of 5,077,555. Tevogen Bio Holdings Inc. has a 12 month low of $0.26 and a 12 month high of $7.61. The company's fifty day simple moving average is $1.36 and its 200 day simple moving average is $1.16.

Analysts Set New Price Targets

Separately, D. Boral Capital began coverage on Tevogen Bio in a report on Tuesday, March 4th. They issued a "buy" rating and a $10.00 target price on the stock.

Remove Ads

Institutional Investors Weigh In On Tevogen Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in Tevogen Bio during the 4th quarter valued at $38,000. JPMorgan Chase & Co. boosted its position in shares of Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares during the last quarter. Barclays PLC increased its holdings in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after buying an additional 12,847 shares in the last quarter. XTX Topco Ltd purchased a new position in Tevogen Bio in the 4th quarter worth about $55,000. Finally, HGC Investment Management Inc. bought a new position in Tevogen Bio during the 3rd quarter valued at about $82,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.